ArticleBMC nephrology2025
Urinary stress hormones and their metabolites as predictive biomarkers for CKD with diabetes.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
aimsThis study aimed to characterize urinary stress hormones and their metabolites in patients with chronic kidney disease associated with diabetes (CKD with diabetes) and to evaluate their associations with renal function, providing insights into stress-related mechanisms and potential biomarker utility. MATERIALS AND
methodsWe enrolled 735 participants, including 449 with type 2 diabetes mellitus(T2D)and 286 with CKD with diabetes. Urinary concentrations of norepinephrine, cortisol, aldosterone, and 17-ketosteroids were analyzed. Statistical methods included correlation and regression analyses, receiver operating characteristic (ROC) curves, and orthogonal partial least squares discriminant analysis (OPLS-DA) to evaluate diagnostic value.
resultsUrinary norepinephrine, cortisol, and 17-ketosteroids levels were significantly lower in CKD patients with diabetes than in those with diabetes alone. Norepinephrine was inversely correlated with albumin-to-creatinine ratio, urinary microalbumin, blood urea nitrogen, and serum creatinine, and positively with estimated glomerular filtration rate. Similar trends were observed for cortisol and 17-ketosteroids. Aldosterone was also negatively correlated with urinary microalbumin and creatinine. OPLS-DA showed distinct metabolic profiles between CKD with diabetes and diabetes, suggesting metabolic heterogeneity. Multivariate logistic regression identified norepinephrine as an independent protective factor, while diastolic blood pressure, urinary glucose, and homovanillic acid were risk factors. A composite model integrating norepinephrine, 17-ketosteroids, and homovanillic acid demonstrated high diagnostic performance, with the norepinephrine-based model achieving an AUC of 0.831 in validation.
conclusionUrinary adrenal hormones and their metabolites provide valuable insights into stress-related mechanisms in CKD with diabetes and may hold potential as complementary noninvasive biomarkers for disease assessment. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.